Core Points - Coeptis Therapeutics Holdings, Inc. has extinguished its convertible note with YA II PN, Ltd, clearing its outstanding debt obligations to Yorkville [1][2] - The CEO stated that this action strengthens the company's capital structure and positions it well for long-term goals, including potential operations in the cryptocurrency space [2] - Coeptis focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases through its subsidiaries [3][4] Company Overview - Coeptis Therapeutics Holdings includes subsidiaries such as Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies, emphasizing biopharmaceutical and technology advancements [3] - The therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology in collaboration with the University of Pittsburgh and other distinguished medical researchers [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [5] - These technologies are intended to optimize business processes and improve overall efficiency [5] Compliance and Standards - The company is headquartered in Wexford, PA, and is committed to advancing its mission within the regulatory framework set by the FDA, ensuring compliance and high standards of patient care [6]